Biosyent investor

Author: undv

August undefined, 2024

WebMar 24, 2024 · BioSyent Inc. is a Canada-based pharmaceutical company. The Company is focused on in-licensing or acquiring pharmaceutical and other healthcare products. It owns a legacy business that manufactures and markets Protect-It, a bio-friendly non-toxic product used in agriculture, which is operated by its subsidiary Hedley Technologies Ltd. http://www.biosyent.com/rx/home/

RX Competitors 2024 BioSyent Alternatives

WebSep 29, 2024 · BioSyent climbed a long way after the early 2024 pandemic pullback. The stock went from about $3.20 to $8.00 before the year was out. But 2024 has been a bit of … WebBioSyent Inc. Listed on the TSX Venture Exchange (TSXV: RX) BioSyent is a profitable growth oriented speciality pharmaceutical company which searches the globe to in … chronic postoperative endophthalmitis

BioSyent to Present at the Virtual MicroCap Leadership Summit

WebNov 17, 2024 · BioSyent Inc. E-Mail: [email protected] Phone: 905-206-0013 Web: www.biosyent.com. This press release may contain information or statements that … WebMar 24, 2024 · Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product ... WebMar 21, 2024 · MISSISSAUGA, Ontario, March 21, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and … der follow-up

BioSyent Releases Q2 and H1 2024 Financial Results

WebNov 15, 2012 · TORONTO, ONTARIO--(Marketwire - Nov 15, 2012) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) today released a summary of its Third Quarter (Q3) 2012 financial results. - Q3 2012 Sales of $1,575,598 sets an all time quarterly record and grew by 60% over Q3 2011 WebMar 9, 2024 · Investor Takeaway. BioSyent appears to be fairly valued. The company is expected to report Q4 earnings on March 21, 2024, and it will be important to see the percentage growth of FeraMAX sales in ... chronic post nasal drip throat clearingWebMar 31, 2024 · For further information please contact: Mr. Rene C. Goehrum President and CEO BioSyent Inc. E-Mail: [email protected] Phone: 905-206-0013 Web: www.biosyent.com. chronic post nasal drip bad breath

"WebOct 28, 2013 · BioSyent only has 13.5 million shares outstanding (14.5m FD), 43% controlled by the management and the board. BioSyent's CEO Rene Goehrum owns 18% of the company, and CFO Alfred D'Souza owns 11%. Mr. " - Biosyent investor

Biosyent investor

Biosyent is undervalued, this investor says - Cantech Letter

WebBioSyent is continuously is looking to source pharmaceutical products that have been successfully developed and proven to be safe and effective. BioSyent then … WebBioSyent is continuously is looking to source pharmaceutical products that have been successfully developed and proven to be safe and effective. BioSyent then …

Did you know?

http://www.biosyent.com/rx/investor_facts/ WebApr 9, 2024 · The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, …

WebMar 9, 2024 · BioSyent Inc. E-Mail: [email protected] Phone: 905-206-0013 Web: www.biosyent.com. This press release may contain information or statements that are … WebMar 21, 2024 · BioSyent Inc. E-Mail: [email protected] Phone: 905-206-0013 Web: www.biosyent.com. This press release may contain information or statements that are …

WebApr 26, 2024 · MISSISSAUGA, Ontario, April 26, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at the upcoming 2024 Bloom Burton & Co ...

WebMar 21, 2024 · BioSyent Inc. E-Mail: [email protected] Phone: 905-206-0013 Web: www.biosyent.com. This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be …

WebApr 14, 2024 · René Goehrum, President and CEO of BioSyent, will present to investors an overview of BioSyent’s business and corporate activities on April 21 at 11:00 am. Mr. Goehrum will also be available to ... chronic postoperative pain 2021WebApr 26, 2024 · MISSISSAUGA, Ontario, April 26, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that it will be presenting at … der forsthof st johannWebMar 24, 2024 · BioSyent Inc. is a Canada-based pharmaceutical company. The Company is focused on in-licensing or acquiring pharmaceutical and other healthcare products. It … der forthofWebMar 19, 2024 · BioSyent Inc. E-Mail: [email protected] Phone: 905-206-0013 Web: www.biosyent.com. TRENDING. Yahoo TV 'Succession' storylines reportedly inspired by Fox News owner Rupert Murdoch's family. chronic postoperative painWebBioSyent Inc. E-Mail: [email protected] Phone: 905-206-0013 Web: www.biosyent.com. This press release may contain information or statements that are … chronic post nasal drip treatmentsWebMar 31, 2024 · BioSyent Inc. E-Mail: [email protected] Phone: 905-206-0013 Web: www.biosyent.com. This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be … der freeway riderWebBioSyent is continuously looking to source pharmaceutical products that have been successfully developed and proven to be safe and effective. BioSyent then managesthese products through the regulatory process and product registration (approval); and once approved, BioSyent markets these products throughout Canada. These … chronic postoperative pain icd 10